Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group
Abstract Objective The objective of this multicenter, real-world study, designed by the Greek Research Alliance for the Study of headache and Pain (GRASP), was to prospectively evaluate the 6-month effectiveness and safety of eptinezumab 100 mg for migraine prophylaxis in difficult-to-treat patients...
保存先:
| 主要な著者: | , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2026-01-01
|
| シリーズ: | The Journal of Headache and Pain |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s10194-026-02275-5 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|